Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Huber

Showing results (821-830 of 859) with videos related to

Pageof 86
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Plos One|February 18, 2010
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptorsMiguel Aste-Amézaga, Ningyan Zhang, Janet E Lineberger, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Science Advances|March 23, 2022
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8Thomas Walle, Joscha A Kraske, Boyu Liao, et al.
Signal Transduction and Targeted Therapy|February 2, 2026
Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosisLi Li, Ramon Lopez Perez, Khuram Shehzad, et al.
Oncoimmunology|December 19, 2024
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7<sup>th</sup> immunorad conferencePierre-Antoine Laurent, Fabrice André, Alexandre Bobard, et al.
Nature|November 5, 2015
Brain tumour cells interconnect to a functional and resistant networkMatthias Osswald, Erik Jung, Felix Sahm, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.
Pageof 86

Showing results (821-830 of 859) with videos related to

Sort By:
Pageof 86
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Plos One|February 18, 2010
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptorsMiguel Aste-Amézaga, Ningyan Zhang, Janet E Lineberger, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Science Advances|March 23, 2022
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8Thomas Walle, Joscha A Kraske, Boyu Liao, et al.
Signal Transduction and Targeted Therapy|February 2, 2026
Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosisLi Li, Ramon Lopez Perez, Khuram Shehzad, et al.
Oncoimmunology|December 19, 2024
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7<sup>th</sup> immunorad conferencePierre-Antoine Laurent, Fabrice André, Alexandre Bobard, et al.
Nature|November 5, 2015
Brain tumour cells interconnect to a functional and resistant networkMatthias Osswald, Erik Jung, Felix Sahm, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.
Pageof 86